Current issues in Hereditary Angioedema (HAE) - Ipopi

More documents

Recommendations

Info

Treatment of C1 inhibitor deficiency -icatibant (Firazyr) Mean VAS scores vs. time for the primary symptom Mean VAS [mm] 100 90 80 70 60 50 40 30 20 10 0 Icatibant (JE049 #2102) Tranexamic acid Icatibant (JE049 #2103) Placebo 0 1 2 3 4 5 6 7 8 9 10 11 12 Time point [h]
Treatment of C1 inhibitor deficiency -ecallantide (DX88; Kalbitor) • Effectıve • Subcutaneous – Kallikrein inhibitor – Produced in pichia pastoris (recombinant protein) • Short half life – 2 hours Avaılable ın USA
Page 1 and 2: Current issues in Hereditary Angioe
Page 3 and 4: What is HAE (Hereditary • HAE 1 o
Page 5 and 6: C1 inhibitor controls inflammation
Page 7 and 8: What have we learnt about the new
Page 9 and 10: • Berinert (C1 inhibitor) trials
Page 11 and 12: Treatment of C1 inhibitor deficienc
Page 13 and 14: Icatibant (Firazyr) • Recurrent a
Page 15 and 16: Living with hereditary angioedema:
Page 17 and 18: L’s story: 25 year old with HAE
Page 19: L’s story •15 th March 2010- 2
Page 23 and 24: Self administration C1 ınhıbıtor
Page 25 and 26: C1 inhibitor controls local Healthy
Page 27: Rational use of steroids….
Page 30 and 31: Mr B 15 years • Unwilling to trai
Page 32 and 33: Mrs B 42 years • Danazol 100 mg a
Page 34 and 35: Need to control acute attacks
Page 36 and 37: What does everyone want • Patient
Page 38: Recent initiatives • World consen

Current issues in Hereditary Angioedema (HAE) - Ipopi

Create successful ePaper yourself

Delete template?

Save as template?